SCHEMBL2906827

SCHEMBL2906827

OCCNC(c1ccc(-c2ccc(F)cc2)cc1)c1c[nH]nc1-c1ccco1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.40
PIK3R1 P27986 1/20 0.39
PIK3CA P42336 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38
ADORA1 P30542 3/20 0.36
ADORA2A P29274 2/20 0.36
ADORA2B P29275 2/20 0.36
ALDH1A1 P00352 3/20 0.34
MAPT P10636 3/20 0.34
MEN1 O00255 2/20 0.34
POLB P06746 2/20 0.34
KMT2A Q03164 2/20 0.34
HPGD P15428 2/20 0.34
KDM4E B2RXH2 1/20 0.34
THRB P10828 1/20 0.34
ESR2 Q92731 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
UBE2I P63279 1/20 0.34
CACNA1B Q00975 1/20 0.34
APBA1 Q02410 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2901868 0.91 PIK3R1 (0.39) AKT1PIK3R1PIK3CAPTGDR2ADORA1
SCHEMBL2901811 0.88 AKT1 (0.39) AKT1ADORA1ADORA2AALDH1A1MAPT
SCHEMBL2908485 0.84 AKT1 (0.36) AKT1ALDH1A1MAPTMEN1POLB
SCHEMBL2901803 0.75 PIK3R1 (0.35) PIK3R1PIK3CAPTGDR2ADORA1ADORA2A
SCHEMBL2903266 0.71 P4HB (0.41) PIK3R1PIK3CAADORA1ADORA2AADORA2B
SCHEMBL2904844 0.71 OPRD1 (0.40) PIK3R1PIK3CAADORA1ADORA2AADORA2B
SCHEMBL2905980 0.70 ALDH1A1 (0.42) PTGDR2ALDH1A1MAPTPOLBKDM4E
SCHEMBL2907737 0.70 LMNA (0.33) PIK3R1PIK3CAPTGDR2ADORA1ADORA2A
SCHEMBL2902356 0.68 MEN1 (0.41) PIK3R1PIK3CAPTGDR2ADORA1ADORA2A
SCHEMBL2909335 0.68 HRH3 (0.43) PIK3R1PIK3CAALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A AKT1 4108/4885PIK3R1 2479/4885PIK3CA 3500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.